Advaxis Reports Second Quarter Ended April 30, 2022
Announced Publication of ADXS-PSA Data in The Oncologist Presented Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in...
Source: globenewswire.com
Page 13 - Ongoing Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Ongoing Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Ongoing Phase Today - Breaking & Trending Today
ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
06.06.2022 - - Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment - - Safety and tolerability allow for continued dose escalation with no dose limiting toxicities to date - SAN ... Seite 1
Source: wallstreet-online.de
CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies - Press Release
- CYT-0851 has demonstrated broad clinical activity and a generally well tolerated safety profile in a heavily pretreated population of patients - Dur
Source: wiredprnews.com
DGAP-News: Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update
Issuer: Immunic, Inc. / Key word(s): Study results Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis
Source: finanznachrichten.de
Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update
– Trial Did Not Achieve Primary Endpoint in the Ulcerative Colitis (UC) Population Caused by Unexpected Interference Between Vidofludimus Calcium and...
Source: prnewswire.com